Clinical trial
Sorafenib and Bortezomib in Treating Patients With Advanced Cancer
NCT00303797 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00303797 |
|---|---|
| Title | Sorafenib and Bortezomib in Treating Patients With Advanced Cancer |
| Official title | A Phase I Study of the Raf Kinase/VEGFR Inhibitor BAY 43-9006 in Combination With the Proteasome Inhibitor PS-341 in Patients With Advanced Malignancies |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific |
| Intervention type | Drug |
| Interventions | 17-N-allylamino-17-demethoxygeldanamycin/bortezomib, sorafenib tosylate |
| Enrollment | 50 |
| Start date | Dec 1, 2005 |
| Primary completion | May 1, 2010 |
| First posted | Mar 17, 2006 |
| Last update posted | Mar 19, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: